Endometrial cancer is the most common malignancy of the female genital tract in developed countries. To identify genetic variants associated with endometrial cancer risk, we performed a genome-wide association study involving 1,265 individuals with endometrial cancer (cases) from Australia and the UK and 5,190 controls from the Wellcome Trust Case Control Consortium. We compared genotype frequencies in cases and controls for 519,655 SNPs. Forty seven SNPs that showed evidence of association with endometrial cancer in stage 1 were genotyped in 3,957 additional cases and 6,886 controls. We identified an endometrial cancer susceptibility locus close to HNF1B at 17q12 (rs4430796, P = 7
l e t t e r S cancer is associated with increased risk of the disease [6] [7] [8] . Although germline mutations in mismatch repair genes confer a substantial risk of endometrial cancer in the context of Lynch syndrome, these are rare 9 . Candidate gene association studies have implicated CYP19A1 as a common endometrial cancer susceptibility locus with modest effect 10, 11 , but no GWAS of endometrial cancer have been published to date.
We have conducted a GWAS using cases with endometrial cancer from Australia and the UK. To reduce the potential effects of disease heterogeneity, we selected cases with endometrioid histology for genotyping using the Human 610K array on the Illumina Infinium platform. We extracted control data for SNPs included on the 610K platform from existing Illumina 1.2M genome-wide scan data for controls of European-ancestry from two UK population-based studies genotyped by the Wellcome Trust Case Control Consortium 12 . After applying standard quality control measures (Online Methods), we analyzed data for 519,655 SNPs from 1,265 cases and 5,190 controls. We compared genotype frequencies between cases and controls using a 1-degreeof-freedom Cochran-Armitage trend test. The test statistic inflation factor (λ) was 1.04 after adjustment for population stratification using the principal components approach 13 ( Supplementary Fig. 1 ). Following a review of cluster plots to eliminate likely artifactual associations, 130 SNPs were significant at P < 10 −4 compared to the ~52 SNPs expected by chance. Next, we eliminated redundant SNPs (Online Methods). In total, we selected 49 SNPs for follow up in stage 2, 47 of which passed genotype quality control (Supplementary Table 1) . We collated data from up to 3,957 endometrial cancer cases and 6,886 controls of European ancestry from ten centers, with genotypes generated specifically for this study or data derived from existing GWAS scans (Supplementary Table 2) .
After combining results from stage 1 and 2 (Supplementary Table 1) , three SNPs were significant at the P < 10 −7 level. All three lie in a region of linkage disequilibrium (pairwise r 2 = 0.68-0.90 in Europeans) encompassing the first four exons of HNF1B at 17q12 ( Table 1) . The most significant association was for rs4430796 (odds ratio (OR) per G allele = 0.84, 95% CI 0.79-0.89, P = 7.1 × 10 −10 ). There was no significant heterogeneity in the per-allele OR between stages 1 and 2 (stage 1 OR = 0.79, 95% CI 0.73-0.87; stage 2 OR = 0.87, 95% CI 0.81-0.94; heterogeneity P = 0.11) or among the five stage 2 studies in which it was genotyped (heterogeneity P = 0.75) (Fig. 1) . There was no significant deviation from the multiplicative, per-allele model (P = 0.74). Restricting stage 2 of the analysis to cancers with an endometrioid histology (1,786 of 2,332 cases genotyped for this SNP) slightly strengthened the effect (stage 2 OR = 0.84, 95% CI 0.77-0.91, overall P = 4.3 × 10 −11 ; Table 1 ). The three HNF1B SNPs were not significantly associated with non-endometrioid disease (Table 1) , although the numbers of cases with this type of disease were small. In addition, we genotyped 832 cases and 2,049 controls of Chinese ancestry from Shanghai (Supplementary Table 2 ) for rs11651755, a surrogate for rs4430796 (HapMap r 2 = 1.0 in the CHB population). The estimated odds ratio for rs11651755 in the Chinese samples was 0.96 (95% CI 0.84-1.09, P = 0.55).
The only SNP outside the HNF1B region to reach P < 10 −5 was rs673604 on 1p34, located 29 kb centromeric to SFPQ (combined OR = 1.21, 95% CI 1.12-1.32, P = 5.9 × 10 −6 ). Although highly significant in stage 1 (P = 6.1 × 10 −7 ), this SNP showed only weak evidence for association in stage 2 (P = 0.041). This stage 2 result was similar when restricted to cases with endometrioid histology (P = 0.049, combined OR = 1.23, 95% CI 1.12-1.34, P = 4.6 × 10 −6 ) or non-endometrioid histology (stage 2 OR = 1.07, 95% CI 0.88-1.30, P = 0.50) (Supplementary Tables 3 and 4) . Further large studies will be required to determine whether this association is genuine. Results for the remaining SNPs investigated in stage 2 were also little different when analyses were restricted to cases of endometrioid or nonendometrioid subtype; three SNPs showed significant differences in frequencies between cases with and without endometrioid histology (P < 0.05), which is in line with what would be expected by chance (Supplementary Tables 3 and 4) .
Multiple studies have independently reported the G allele of rs4430796, associated with decreased risk of endometrial cancer in this study, to be associated with a decreased risk of prostate cancer [14] [15] [16] . A recent meta-analysis estimated an OR per G allele of 0.79 (95% CI 0.76-0.83) for prostate cancer 17 but found no association of the same allele with breast, lung, colorectal or pancreatic cancers or 19 , but the association between HNF1B SNPs and prostate cancer does not appear to be mediated by history of diabetes 20 . Increased body mass index (BMI) is a major risk factor for both type 2 diabetes and endometrial cancer, and there is a positive correlation between type 2 diabetes and endometrial cancer risk [21] [22] [23] [24] . However, the opposite direction of the effects of rs4430796 on endometrial cancer and type 2 diabetes risk indicates that the association between rs4430796 and endometrial cancer risk is not mediated through BMI or type 2 diabetes. In addition, in the subset of endometrial case-control studies where BMI was recorded, adjusting for BMI did not materially alter the risk estimate (OR = 0.87 (95% CI 0.78-0.97) compared to OR = 0.88 (95% CI 0.79-0.99); n = 3,055).
To provide a more comprehensive analysis of SNPs in the HNF1B region, we identified variants in the region using re-sequencing data in individuals of European ancestry from the 1000 Genomes Project and performed association analyses for all SNPs using genotypes imputed from the stage 1 data. We identified 20 SNPs associated with endometrial cancer at P < 10 −5 , the most significant being rs11651755 (Supplementary Table 5 ). All these SNPs are strongly correlated with rs4430796 (r 2 > 0.45). It is plausible therefore that one or more of these variants is functionally associated with endometrial cancer risk.
The common haplotypes formed by the 33 SNPs from the 1000 Genomes Project are well tagged by the six SNPs genotyped in stage 1 of our study (rs757210, rs4430796, rs4239217, rs7501939, rs3760511 and rs1762642). For example, the rare allele of rs11651755 appears to always occur on the same haplotype as the rare allele of rs4430796. We found no evidence of specific haplotype effects at this locus; the haplotypes carrying the common A allele at rs4430796 were all more frequent in cases than controls, and the reverse was true for three of four haplotypes carrying the protective G allele (Supplementary Table 6) .
HNF1B (also known as TCF2, LFB3 MODY5 and VHNF1) encodes a member of the homeodomain-containing superfamily of transcription factors. The gene encodes three isoforms, with isoforms A and B considered to act as transcriptional activators and isoform C as a transcriptional repressor 25 . Abrogating mutations in HNF1B result in diabetes phenotypes, including maturity-onset diabetes of the young subtype 5 (MODY5) as well as renal cysts. Of relevance to endometrial cancer, microdeletions encompassing HNF1B have been reported in Mayer-Rokitansky-Kuster-Hauser syndrome, which is characterized by congenital aplasia of the uterus and upper vagina due to anomalous development of the Mullerian ducts 26 , and HNF1B mutations or deletions are associated with uterine abnormalities caused by incomplete Mullerian duct fusion and Mullerian duct aplasia 27 . Human embryonic gene expression studies have shown that HNF1B expression occurs during early development of the human urogenital tract, with expression maintained in Wolffian duct derivatives but not in Mullerian duct deriviatives 28 . In contrast, HNF1B overexpression has been reported to be a biomarker of clear-cell carcinoma of the pancreas 29 and of clear-cell carcinoma of the ovary and its probable precursor ovarian endometriosis [30] [31] [32] [33] . There is also evidence to suggest that HNF1B isoform usage may be altered in prostate cancer tissue, with upregulated HNF1B isoform B expression in prostate cancer tissue as compared to benign tissue 34 . Analysis of several lymphocyte-derived gene expression datasets (Supplementary Fig. 2 ) identified significant associations between rs4430796 genotype and HNF1B expression in individuals of European ancestry but not for individuals of African ancestry. These observations suggest that HNF1B may underlie the observed association with endometrial cancer risk, but that rs4430796 is unlikely to be the causal SNP driving the association.
GWAS have so far identified 29 prostate cancer loci in addition to HNF1B (ref. 35) , but none of the other loci showed any evidence of association with endometrial cancer in this study (Supplementary Table 7 ). Further common low penetrance endometrial cancer loci are likely to be identifiable through larger collaborative GWAS and follow-up studies. The independent discovery of a common risk allele for both prostate cancer and endometrial cancer indicates some shared etiology between these two diseases that had not previously been recognized and also highlights the value of the agnostic GWAS approach for identifying previously unexplored biological pathways and new molecular targets for prevention. We thank the study participants and collaborators and the research teams involved in the design and implementation of the individual studies Table 2 and Supplementary Note).
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Genotyping and quality control. Genotypes for stage 1 cases were generated using an Illumina Infinium 610K array and called using the Illumina GenCall algorithm. Controls were genotyped using an Illumina Infinium 1.2M array as part of WTCCC2 and called using the Illuminus algorithm using genotypes that were successfully called with posterior probability >0.95 (ref. 37) . Analyses were restricted to the 519,655 SNPs meeting the following criteria: call rate ≥95% if minor allele frequency (MAF) ≥ 5% (or call rate ≥ 99% if MAF < 5%), Hardy-Weinberg equilibrium (HWE) P > 10 −12 (cases) or HWE P > 10 −7 with no difference in frequency between the two WTCCC2 control groups at P < 10 −6 (controls). The duplicate concordance was 99.998%.
Genotypes were available for 1,344 cases with endometrial cancer. A subset of individuals was identified for exclusion as follows: two individuals with probable Turner's syndrome and two males based on genotypes for markers on the X and Y chromosomes; samples with call rate <97% (n = 14); samples with heterozygosity <0.65 or >0.68 (n = 11); the sample with the lower call rate from two probable sibling pairs and 26 duplicate pairs, identified as close relatives by identity-by-state probabilities >0.85; eight individuals with >15% non-European ancestry as indicated from computing identity-by-state scores between participants and individuals in HapMap and multidimensional scaling. Twenty-one cases were also excluded from the final analysis of stage 1 because of unresolved discrepancies between their stage 1 and stage 2 genotypes, leaving a total of 1,265 cases. The WTCCC2 control data (5,190 individuals) had been cleaned for a previous study 38 to remove probable close relatives and individuals with >15% estimated non-European ancestry, low or high heterozygosity (<0.65 or >0.68) or call rate <97%.
Genotyping for stage 2 was performed as indicated in Supplementary Table 2 . All studies complied with quality-control standards by including ≥2 no DNA template controls per 384-well assay plate, ≥2% of samples in duplicate, genotyping call rate >95% and ≥98% concordance between duplicated samples for each SNP assay. The raw data were reviewed for sample sets with evidence for departure from HWE using the χ 2 test (1 d.f.) as a marker of poor genotyping quality. Plates or studies with HWE P < 0.0001 were automatically excluded from combined analysis.
Statistical methods. Stage 1 genotype frequencies were compared between cases and controls using the 1-degree-of-freedom Cochran-Armitage trend (per-allele) test. Population stratification was adjusted for using the first three principal components of the genomic kinship matrix, as estimated using 28,494 uncorrelated SNPs (r 2 < 0.1). The inflation factor was computed from the lower 90% of the χ 2 statistics.
